Imagia Canexia Health’s precision oncology solutions digitize biologic samples and make high-quality genomic information accessible and affordable.
Our targeted assays are cost-effective, rapidly scalable, and available for tissue or blood samples. Our Clinical Services team can help you safely optimize and validate NGS profiling within your own laboratory—library preparation, sequencing, report issuing, and sign-off take place at your location.
Imagia Canexia Health’s Find It & Fusions panels detect mutations and gene fusion events in solid tumor tissue. Tissue profiling can be used to help inform treatment decisions or predict progression of cancer based on somatic mutations found in the tumor.
Imagia Canexia Health’s Follow It panel detects mutations in plasma. Plasma profiling (a type of liquid biopsy) can be used to help tailor treatment, monitor cancer progression, or detect treatment resistance.
Our comprehensive, secure, informatics and reporting platform delivers automated detailed results, therapeutic recommendations, and expertly curated clinical trials. Our platform, your insights for more informed treatment decisions.
Access Canexia Health’s full stack of bioinformatics, reporting, and quality assurance tools, right from the cloud.
Contact us to learn more about our assays, informatics, or support, and learn more about becoming an Imagia Canexia Health partner.
May 4, 2021
Microsatellites are short, repeating DNA segments that can play a major role in studying cancers.
March 2, 2021
Canexia Health’s Chief Scientific Officer writes about the importance of combining different approaches to obtain correct results for ctDNA diagnostics. While high sensitivity is important, it must be contextualized with other key measurements.
July 15, 2020
A consortium led by Vancouver-based Canexia Health (formerly Contextual Genomics) will enable access to critical testing and treatment options for Canadian cancer patients during the COVID-19 pandemic.